Meeder Asset Management Inc Jounce Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

$1.48 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$7.11 - $9.64 $25,439 - $34,491	-3,578 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$5.04 - $8.73 $1,869 - $3,238	371 Added 11.57%	3,578 $27,000
Q2 2021 Aug 09, 2021	SELL	$6.58 - $10.66 $2,408 - $3,901	-366 Reduced 10.24%	3,207 $22,000
Q1 2021 Apr 28, 2021	BUY	$6.73 - $13.87 $24,046 - $49,557	3,573 New	3,573 $37,000
Q4 2020 Feb 09, 2021	SELL	$6.37 - $10.33 $21,982 - $35,648	-3,451 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$4.58 - $10.95 $2,665 - $6,372	-582 Reduced 14.43%	3,451 $29,000
Q2 2020 Aug 11, 2020	BUY	$4.17 - $7.58 $12,831 - $23,323	3,077 Added 321.86%	4,033 $28,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $32,574 - $97,387	-11,194 Reduced 92.13%	956 $5,000
Q4 2019 Feb 13, 2020	SELL	$2.81 - $9.21 $22,449 - $73,578	-7,989 Reduced 39.67%	12,150 $106,000
Q3 2019 Oct 17, 2019	BUY	$3.33 - $4.93 $50,299 - $74,467	15,105 Added 300.06%	20,139 $68,000
Q2 2019 Aug 05, 2019	BUY	$4.3 - $6.73 $15,454 - $24,187	3,594 Added 249.58%	5,034 $25,000
Q1 2019 Apr 16, 2019	SELL	$3.43 - $6.87 $4,733 - $9,480	-1,380 Reduced 48.94%	1,440 $9,000
Q4 2018 Jan 17, 2019	BUY	$2.69 - $6.71 $2,114 - $5,274	786 Added 38.64%	2,820 $9,000
Q3 2018 Nov 02, 2018	BUY	$6.5 - $8.37 $11,914 - $15,342	1,833 Added 911.94%	2,034 $0
Q2 2018 Jul 24, 2018	SELL	$7.27 - $21.88 $450 - $1,356	-62 Reduced 23.57%	201 $0
Q1 2018 May 03, 2018	BUY	$13.4 - $28.4 $3,524 - $7,469	263 New	263 $6,000
Q4 2017 Feb 02, 2018	SELL	$12.52 - $17.82 $6,134 - $8,731	-490 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$11.17 - $16.99 $5,473 - $8,325	490	490 $8,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.

Account